Patents by Inventor Kiyotaka Kuzushima

Kiyotaka Kuzushima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cytotoxic T-cell epitope peptides that specifically attack epstein-barr virus-infected cells and uses thereof
    Patent number: 8481051
    Abstract: The present inventors introduced mRNAs for the Epstein-Barr virus proteins LMP1 and EBNA1 into antigen-presenting cells, and as a result, demonstrated that the cells induced Epstein-Barr virus-specific cytotoxic T cells. The present inventors also demonstrated that the cytotoxic T cells recognized epitope peptides presented via HLA-A*0206, HLA-Cw*0303, or HLA-Cw*0304, inhibited the outgrowth of Epstein-Barr virus-infected B cells, and lysed Epstein-Barr virus-infected NK lymphomas and NK cells.
    Type: Grant
    Filed: October 27, 2006
    Date of Patent: July 9, 2013
    Assignee: Medical and Biological Laboratories Co., Ltd.
    Inventors: Kiyotaka Kuzushima, Yoshinori Ito, Ayako Okamura, Yoshiki Akatsuka, Yasuo Morishima
  • Epitope/peptide recognized by HLA-A2402-restricted Ep-CAM-specific CTL and use of the same
    Patent number: 7846651
    Abstract: A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 or 2 by addition, deletion or substitution of one or more amino acids, the peptide being capable of forming a complex with an HLA-A2402 molecule to be recognized by HLA-A2402-restricted cytotoxic T lymphocytes or induce such lymphocytes. Such a peptide is useful as a cancer vaccine for epithelial cancer patients having HLA-A2402.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: December 7, 2010
    Assignees: Aichi Prefecture, Otsuka Pharmaceutical Co., Ltd.
    Inventor: Kiyotaka Kuzushima
  • EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRICTED EP-CAM-SPECIFIC CTL AND USE OF THE SAME
    Publication number: 20100167321
    Abstract: A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 or 2 by addition, deletion or substitution of one or more amino acids, the peptide being capable of forming a complex with an HLA-A2402 molecule to be recognized by HLA-A2402-restricted cytotoxic T lymphocytes or induce such lymphocytes. Such a peptide is useful as a cancer vaccine for epithelial cancer patients having HLA-A2402.
    Type: Application
    Filed: September 22, 2009
    Publication date: July 1, 2010
    Applicants: AICHI PREFECTURE, OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Kiyotaka KUZUSHIMA
  • CYTOTOXIC T-CELL EPITOPE PEPTIDES THAT SPECIFICALLY ATTACK EPSTEIN-BARR VIRUS-INFECTED CELLS AND USES THEREOF
    Publication number: 20090305324
    Abstract: The present inventors introduced mRNAs for the Epstein-Barr virus proteins LMP1 and EBNA1 into antigen-presenting cells, and as a result, demonstrated that the cells induced Epstein-Barr virus-specific cytotoxic T cells. The present inventors also demonstrated that the cytotoxic T cells recognized epitope peptides presented via HLA-A*0206, HLA-Cw*0303, or HLA-Cw*0304, inhibited the outgrowth of Epstein-Barr virus-infected B cells, and lysed Epstein-Barr virus-infected NK lymphomas and NK cells.
    Type: Application
    Filed: October 27, 2006
    Publication date: December 10, 2009
    Applicants: MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD, AICHI PREFECTURE
    Inventors: Kiyotaka Kuzushima, Yoshinori Ito, Ayako Okamura, Yoshiki Akatsuka, Yasuo Morishima
  • Epitope/peptide recognized by HLA-A2402-restricted Ep-CAM-specific CTL and use of the same
    Patent number: 7619058
    Abstract: A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 or 2 by addition, deletion or substitution of one or more amino acids, the peptide being capable of forming a complex with an HLA-A2402 molecule to be recognized by HLA-A2402-restricted cytotoxic T lymphocytes or induce such lymphocytes. Such a peptide is useful as a cancer vaccine for epithelial cancer patients having HLA-A2402.
    Type: Grant
    Filed: January 19, 2005
    Date of Patent: November 17, 2009
    Assignees: Aichi Prefecture, Otsuka Pharmaceutical Co.
    Inventor: Kiyotaka Kuzushima
  • Epitope/Peptide Recognized By Hla-A2402-Restricted Ep/Cam-Specific Ctl And Use Of The Same
    Publication number: 20090010951
    Abstract: A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 or 2 by addition, deletion or substitution of one or more amino acids, the peptide being capable of forming a complex with an HLA-A2402 molecule to be recognized by HLA-A2402-restricted cytotoxic T lymphocytes or induce such lymphocytes. Such a peptide is useful as a cancer vaccine for epithelial cancer patients having HLA-A2402.
    Type: Application
    Filed: January 19, 2005
    Publication date: January 8, 2009
    Inventor: Kiyotaka Kuzushima